Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

War in Ukraine: The International Brain Tumour Alliance's response to aiding...

Kathy Oliver - Chair and Co-Director, International Brain Tumour Alliance

War in Ukraine: The International Brain Tumour Alliance's response to aiding refugees during the crisis ( Kathy Oliver - Chair and Co-Director, International Brain Tumour Alliance )

Ibrutinib plus venetoclax for 1-L treatment of CLL and small lymphocytic...

Dr Carol Moreno - University of Barcelona, Barcelona, Spain

Ibrutinib plus venetoclax for 1-L treatment of CLL and small lymphocytic lymphoma shows a clinically meaningful PFS ( Dr Carol Moreno - University of Barcelona, Barcelona, Spain )

Rucaparib effective as maintenance therapy following first-line platinum-based...

Dr Bradley Monk - University of Arizona College, Tucson, USA

Rucaparib effective as maintenance therapy following first-line platinum-based chemo in ovarian cancer ( Dr Bradley Monk - University of Arizona College, Tucson, USA )

RAGNAR study evidences efficacy and safety of erdafitinib in patients with...

Dr Yohann Loriot - Institut Gustave Roussy, Villejuif, France

RAGNAR study evidences efficacy and safety of erdafitinib in patients with advanced FGFR+ malignancies ( Dr Yohann Loriot - Institut Gustave Roussy, Villejuif, France )

ASCO 2022: The latest in mRCC

Prof James Larkin, Dr Bernard Escudier, Prof Jens Bedke and Dr Toni Choueiri

ASCO 2022: The latest in mRCC ( Prof James Larkin, Dr Bernard Escudier, Prof Jens Bedke and Dr Toni Choueiri )

Comment: Addition of ixazomib to pomalidomide and dexamethasone improves...

Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA

Comment: Addition of ixazomib to pomalidomide and dexamethasone improves survival for multiple myeloma patients ( Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA )

A bispecific antibody talquetamab shows promising efficacy in relapsed...

Prof Monique Minnema - University Medical Center Utrecht, Utrecht, Netherlands

$A bispecific antibody talquetamab shows promising efficacy in relapsed/refractory multiple myeloma ( Prof Monique Minnema - University Medical Center Utrecht, Utrecht, Netherlands )$

Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy...

Dr Elias Mai - University Hospital Heidelberg, Heidelberg, Germany

Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy show a superior MRD negativity rate for newly diagnosed MM patients ( Dr Elias Mai - University Hospital Heidelberg, Heidelberg, Germany )

The abscopal effect of radiotherapy and nivolumab in relapsed or refractory...

Dr Paul Bröckelmann - University of Cologne, Cologne, Germany

$The abscopal effect of radiotherapy and nivolumab in relapsed or refractory Hodgkin lymphoma ( Dr Paul Bröckelmann - University of Cologne, Cologne, Germany )$

Quizartinib improves overall survival in adult patients with FLT3-ITD+ acute...

Dr Harry Erba - The Duke Cancer Institue, Durham, USA

Quizartinib improves overall survival in adult patients with FLT3-ITD+ acute myeloid leukaemia ( Dr Harry Erba - The Duke Cancer Institue, Durham, USA )

Adagrasib shows CNS penetration and encouraging intracranial activity for...

Dr Joshua Sabari - Perlmutter Cancer Center NYU Langone Health, New York, USA

Adagrasib shows CNS penetration and encouraging intracranial activity for KRASG12C-mutated NSCLC and active, untreated CNS metastases ( Dr Joshua Sabari - Perlmutter Cancer Center NYU Langone Health, New York, USA )

ASCO 2022: Head and neck cancer highlights

Dr Mark Persky - NYU Langone’s Perlmutter Cancer Center, New York, USA

ASCO 2022: Head and neck cancer highlights ( Dr Mark Persky - NYU Langone’s Perlmutter Cancer Center, New York, USA )

More from ecancer